Skip to main content
Top
Published in: Drugs 12/2022

Open Access 01-08-2022 | Oral Contraception | Correction

Correction: Estetrol/Drospirenone: A Review in Oral Contraception

Authors: Arnold Lee, Yahiya Y. Syed

Published in: Drugs | Issue 12/2022

Login to get access

Excerpt

The article “Estetrol/Drospirenone: A Review in Oral Contraception”, written by Arnold Lee and Yahiya Y. Syed, was originally published Online First without Open Access. After publication in volume 82, issue 10, pages 1117–1125 Gedeon Richter, Estetra SRL (an affiliate company of Mithra Pharmaceuticals, Liège, Belgium), and Mayne Pharma, LLC requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Gedeon Richter, Estetra SRL (an affiliate company of Mithra Pharmaceuticals, Liège, Belgium), and Mayne Pharma, LLC. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by-nc/​4.​0/​. …
Metadata
Title
Correction: Estetrol/Drospirenone: A Review in Oral Contraception
Authors
Arnold Lee
Yahiya Y. Syed
Publication date
01-08-2022
Publisher
Springer International Publishing
Published in
Drugs / Issue 12/2022
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-022-01760-w

Other articles of this Issue 12/2022

Drugs 12/2022 Go to the issue

AdisInsight Report

Linzagolix: First Approval